fyn related Src family tyrosine kinaseGenealiases: GTK · PTK5 · RAK
Q-omics provides the consensus-scored FRK profile across patient tissues and cancer cell-line models. FRK expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FRK is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, FRK protein abundance shows 19,687 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where FRK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRK survival associations across molecular data types. FRK RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRK RNA expression–survival associations across cancer types. High FRK expression shows unfavorable associations in OV, HNSC and ESCA, but favorable associations in KIRC, PRAD and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FRK RNA expression.
This table summarizes FRK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FRK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRK shows lower tumor expression in KIRC, THCA and KICH and higher tumor expression in STAD, LUAD and BRCA. The KIRC box plot shows higher FRK RNA expression in normal versus tumor tissue (log2 FC = −1.077, t-test p < 0.001).
This table shows molecular features associated with FRK in patient tissues and cancer cell lines. In patient samples, FRK shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FRK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
